pluriel

Pluristem placenta-based cell therapy products Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that the U.S. Administration des aliments et des médicaments (FDA) has cleared Pluristem’s Investigational Drug Application (INDIANA) for a Phase III study of its PLX-PAD cell therapy in the treatment of muscle En savoir plus